Oncobit Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $2.43M

  • Investors
  • 8

Oncobit General Information

Description

Developer of precision diagnostic and monitoring assays designed for personalized cancer care. The company's technology uses digital polymerase chain reaction, circulating tumor DNA analysis, targeted mutation hotspot detection, cloud-based analytics pipelines, liquid biopsy diagnostics, quantitative cancer marker detection, standardized reporting software, and non-invasive monitoring, enabling physicians to monitor disease progression and treatment response.

Contact Information

Website
www.oncobit.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Rütistrasse 16
  • 8952 Schlieren
  • Switzerland
Primary Industry
Outcome Management (Healthcare)
Other Industries
Discovery Tools (Healthcare)
Other Healthcare Technology Systems
Corporate Office
  • Rütistrasse 16
  • 8952 Schlieren
  • Switzerland

Oncobit Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncobit Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Later Stage VC 30-Oct-2025 $2.43M Completed Generating Revenue
13. Later Stage VC (Series A) 19-Nov-2024 Completed Generating Revenue
12. Later Stage VC 12-Nov-2024 Completed Generating Revenue
11. Later Stage VC 30-Apr-2024 Completed Startup
10. Early Stage VC 12-Jan-2022 Completed Startup
9. Seed Round 31-Dec-2021 Completed Startup
8. Debt - General 01-Nov-2021 Completed Startup
7. Seed Round 23-Jun-2021 Completed Startup
6. Seed Round 29-Apr-2021 $2.52M $2.62M Completed Startup
5. Accelerator/Incubator 01-Jan-2021 $100K Completed Startup
To view Oncobit’s complete valuation and funding history, request access »

Oncobit Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Pre-series A
Seed Extension
Seed Extension
Seed Extension
Seed preferred
Seed preferred
Ordinary 4,554 $1.254329 $27.54 $27.54 1x $27.54 1.69%
Ordinary 784 $1.254329 $43.9 $43.9 1x $43.9 0.29%
To view Oncobit’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Oncobit Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of precision diagnostic and monitoring assays designed for personalized cancer care. The company's technology
Outcome Management (Healthcare)
Schlieren, Switzerland
10 As of 2024

Los Angeles, CA
 

Austin, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Oncobit Competitors (3)

One of Oncobit’s 3 competitors is EntroGen, a Venture Capital-Backed company based in Los Angeles, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
EntroGen Venture Capital-Backed Los Angeles, CA
Natera Formerly VC-backed Austin, TX
Personalis Formerly VC-backed Fremont, CA
You’re viewing 3 of 3 competitors. Get the full list »

Oncobit Patents

Oncobit Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4594527-A1 Detection method, computer program product, data processing unit and detection system for detecting mutations of a polynucleotide in a biological sample Pending 28-Sep-2022
US-20260185149-A1 Detection method, computer program product, data processing unit and detection system for detecting mutations of a polynucleotide in a biological sample Pending 28-Sep-2022
WO-2024068399-A1 Detection method, computer program product, data processing unit and detection system for detecting mutations of a polynucleotide in a biological sample Inactive 28-Sep-2022 C12Q1/6851

Oncobit Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oncobit Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
ID Solutions (France) Corporation Minority
Kickfund Venture Capital Minority
Avanteca Partners Other Minority
GF Group Holding Corporation Minority
Angel (individual) Minority
You’re viewing 5 of 8 investors. Get the full list »

Oncobit FAQs

  • When was Oncobit founded?

    Oncobit was founded in 2018.

  • Where is Oncobit headquartered?

    Oncobit is headquartered in Schlieren, Switzerland.

  • What is the size of Oncobit?

    Oncobit has 10 total employees.

  • What industry is Oncobit in?

    Oncobit’s primary industry is Outcome Management (Healthcare).

  • Is Oncobit a private or public company?

    Oncobit is a Private company.

  • What is the current valuation of Oncobit?

    The current valuation of Oncobit is .

  • What is Oncobit’s current revenue?

    The current revenue for Oncobit is .

  • How much funding has Oncobit raised over time?

    Oncobit has raised $15M.

  • Who are Oncobit’s investors?

    ID Solutions (France), Kickfund, Avanteca Partners, GF Group Holding, and are 5 of 8 investors who have invested in Oncobit.

  • Who are Oncobit’s competitors?

    EntroGen, Natera, and Personalis are competitors of Oncobit.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process